

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. The authors have reported no funding for this work.

This article is part of a special series devoted to addressing bias, bigotry, racism, and mental health disparities through research, practice, and policy. The series is edited by Assistant Editor Eraka Bath, MD, Deputy Editor Wanjikũ F.M. Njoroge, Associate Editor Robert R. Althoff, MD, PhD, and Editor-in-Chief Douglas K. Novins, MD.

Author Contributions Conceptualization: Naveed, Khosa Data curation: Saboor, Naveed, Safdar, Malik, Khosa Formal analysis: Saboor, Chaudhary Methodology: Saboor, Naveed, Chaudhary, Safdar, Malik, Khosa Supervision: Naveed, Khosa Validation: Saboor, Naveed Writing – original draft: Saboor, Naveed, Chaudhary, Safdar, Malik, Khosa Writing – review and editing: Saboor, Naveed, Chaudhary, Safdar, Malik, Khosa

Disclosure: Dr. Khosa has been the recipient of the May Cohen Equity, Diversity, and Gender Award – Association of Faculties of Medicine of Canada (2020). Drs. Saboor, Naveed, Chaudhary, Safdar, and Malik have reported no biomedical financial interests or potential conflicts of interest.

Correspondence to Sadiq Naveed, MD, MPH, DFAACAP, Institute of Living, 200 Retreat Avenue, Hartford, CT 06102; e-mail: sadiq.naveed@hhchealth.org

0890-8567/\$36.00/©2021 American Academy of Child and Adolescent Psychiatry

https://doi.org/10.1016/j.jaac.2021.04.018

REFERENCES

- Roberts LW, Maldonado Y, Coverdale JH, Balon R, Louie AK, Beresin EV. The critical need to diversify the clinical and academic workforce. Acad Psychiatry. 2014;38: 394-397. https://doi.org/10.1007/s40596-014-0175-y.
- Silver JK, Bean AC, Slocum C, et al. Physician workforce disparities and patient care: a narrative review. Health Equity. 2019;3:360-377. https://doi.org/10.1089/heq.2019.0040.
- Chaudhary AMD, Naveed S, Saboor S, Safdar B, Azeem MW, Khosa F. Gender and racial disparities among US psychiatry residents: a review of trends [published online ahead of print February 13, 2021]; https://doi.org/10.1007/s11126-021-09888-w.
- Kim W. Recruitment. Child Adolesc Psychiatric Clin N Am. 2007;16:45-54. https://doi. org/10.1016/j.chc.2006.09.003.
- Brotherton SE, Etzel SI. Graduate medical education, 2017-2018. JAMA. 2018;320: 1051-1070. https://doi.org/10.1001/jama.2018.10650.
- Accreditation Council for Graduate Medical Education. ACGME Data Resource Book Archives. Accessed March 2021; https://www.acgme.org/About-Us/Publications-and-Resources/Graduate-Medical-Education-Data-Resource-Book.
- Axelson D. Meeting the demand for pediatric mental health care. Pediatrics. 2019;144. https://doi.org/10.1542/peds.2019-2646.
- Takeshita J, Wang S, Loren AW, *et al*. Association of racial/ethnic and gender concordance between patients and physicians with patient experience ratings. JAMA Netw Open. 2020; 3:e2024583. https://doi.org/10.1001/jamanetworkopen.2020.24583.
- Gonzaga AMR, Appiah-Pippim J, Onumah CM, Yialamas MA. A framework for inclusive graduate medical education recruitment strategies: meeting the ACGME standard for a diverse and inclusive workforce. Acad Med. 2020;95:710-716. https://doi.org/10. 1097/acm.000000000003073.
- Jordan A, Jegede O. Building outreach and diversity in the field of addictions. Am J Addict. 2020;29:413-417. https://doi.org/10.1111/ajad.13097.

ncreasing coronavirus disease 2019 (COVID-19)

vaccination rates has been identified by the US

Centers of Disease Control and Prevention as

Implementation and Outcomes of COVID-19 Vaccinations at a Child and Adolescent Psychiatric Hospital



To the Editor:

critical to ending the COVID-19 pandemic.¹ On May 10, 2021, the Pfizer-BioNTech COVID-19 vaccine (BNT162b2; Pfizer, Inc, New York, New York, and Bio-NTech SE, Mainz, Germany) was approved for emergency use authorization by the US Food and Drug Administration for patients 12 years of age or older. Here we report a retrospective study describing the implementation of a COVID-19 vaccination program at our child and adolescent psychiatric hospital. To our knowledge, this is the first report detailing the administration of the COVID-19 vaccination in this setting.

Our facility, a freestanding, 84-bed, academic child and adolescent psychiatric hospital (The University of Kansas Health System [TUKHS]-Marillac campus) began offering COVID-19 vaccinations for all adolescents aged 12-17 years in May 2021. Nurses screened all patients meeting age requirements on admission for COVID-19 vaccination history and willingness to receive vaccination along with contraindications. Contraindications to the vaccine include history of severe allergic reaction or anaphylaxis to polyethylene glycol, history of severe allergic reactions to vaccines or injectable products, received passive antibody treatment for COVID-19, solid organ or stem cell transplant recipient within the last 6 months, or currently COVID-19 positive. For patients screening as both accepting of the vaccine and lacking contraindications, the Pfizer-BioNTech COVID-19 vaccine was ordered per protocol. Both first and second doses were offered to eligible patients. The goal of our study was to assess rates of, side effects of, and barriers to administering COVID-19 vaccines to adolescents admitted to a psychiatric hospital.

We conducted a 4-week retrospective chart review of all patients aged 12-17 years admitted to TUKHS-Marillac campus from May 27, 2021, to June 23, 2021. Our Institutional Review Board approved this study. The results are summarized in Table 1. Overall, 121 patients (68.4%) screened were unvaccinated. Of the 121 unvaccinated patients, 68.6% declined vaccination, and 29.8% requested and consented to vaccination. Overall, 33 vaccinations were administered (29 first doses and 4 second doses). Seven patients who requested the vaccine were unable to receive the vaccination. Reasons that vaccines were not administered included unable to obtain parental consent, being discharged before a vaccine was prepared, discharged on a weekend, and concerns of wasting a vial owing to low number of requests for vaccinations on a specific day. Because most vaccinations occurred on the day of discharge, overall side effects are unknown. However, no adverse events were registered through our reporting system, and no vaccinations delayed discharge.

	All patients screened for vaccine		Patients received COVID-19 vaccine in hospital	
Age, median (range)	14.5	(12—17)	14.5	(12—17)
Sex, n (%)				
Female	114	(65.5)	21	(63.6)
Male	60	(34.5)	12	(36.4)
Race, n (%)				
Caucasian/non-Hispanic	132	(75.9)	30	(90.9)
Black/African American	14	(8.8)	1	(3)
Hispanic/Latino/Spanish origin	6	(3.4)	0	(0)
Other	15	(8.6)	2	(6.1)
Declined	7	(4.0)	0	(O)
Primary discharge diagnosis, n (%)				
Attention-deficit/hyperactivity disorder	8	(4.6)	3	(9.1)
Adjustment disorder	19	(10.9)	2	(6.1)
Anxiety disorder or trauma-related disorder	16	(9.2)	3	(9.1)
Autism spectrum disorder	4	(2.3)	0	(0)
Disruptive mood dysregulation disorder	17	(9.8)	4	(12.1)
Major depressive disorder/suicidal ideations	99	(56.9)	18	(54.5)
Others	11	(6.3)	3	(9.1)
COVID-19 vaccine status on admission, n (%)				
Completion of vaccine series	30	(17.2)	N/A	
Partial completion of vaccine series	23	(13.2)	4	(12.1)
No prior vaccine administration	121	(68.4)	29	(87.9)
Declined vaccine	83/121	(68.6)	N/A	
Unable to assess or no family present	2/121	(1.6)	N/A	
Requested first vaccine in hospital	36/121	(29.8)	N/A	
Contraindication to vaccine	0/36	(0)	N/A	
Requested first vaccine but did not receive it in hospital	7/36	(19.4)	N/A	

Additionally, patients and family members were appreciative that we offered the COVID-19 vaccine in this setting.

Our study found a 29.8% acceptance rate in adolescent inpatients with mental illness and found that 30.5% had already received one dose of the vaccine before admission. This is comparable to the national average on June 30, 2021, with 30.9% of adolescents aged 12–15 years having at least one dose of the vaccine.² However, this is significantly less than a 52% intention rate reported in an April 2021 survey of adolescents.³ The main reasons for vaccine hesitancy found in the aforementioned study were concern over safety and efficacy from parents. Our study was unable to evaluate reasons for vaccine hesitancy in this population, but possible cited reasons could include safety and efficacy concerns, antivaccine movements, distrust in authorities, conspiracy theories, and religious beliefs.⁴ Additionally, previous misinformation of links of vaccines to autism could add to mistrust in vaccines. Remarkably, one study of medically complex youths aged 16–25 years in a long-term care facility had a 100% acceptance rate.⁵ However, these study participants had significant medical comorbidities making them highly vulnerable to the COVID-19 infection. Limitations of our study include its retrospective design and the short evaluation period.

The long-term mental health impact of the COVID-19 pandemic in children and adolescents is relatively unknown. Reduced access to mental health care is a major concern of the pandemic. Our facility is currently at halfcapacity (42 beds), secondary to social distancing recommendations to allow for single occupancy. Patients with mental illness often have reduced medical care, including vaccinations.⁶ Previous studies have demonstrated positive increases in seasonal vaccine rates when vaccines are easily accessible to adults with mental illnesses.⁷ Having vaccines available in an inpatient setting is one way to increase the accessibility for adolescents with mental health diagnoses. It is evident from this study that significant barriers remain to COVID-19 vaccine acceptance within this population. As clinicians, it is essential that we properly educate our patients on the health benefits of the vaccine and dispel misinformation and advocate for all patients with mental illness to have access to the COVID-19 vaccine.

Karen E. Moeller, PharmD, BCPP Matie Meeks, BS Jill Reynoldson, PharmD, BCPP Michell Douglass, MD

Accepted August 26, 2021.

Dr. Moeller and Ms. Meeks are with the School of Pharmacy, The University of Kansas, Lawrence, Kansas. Dr. Reynoldson is with The University of Kansas Health System, Kansas City. Dr. Douglass is with KU-Marillac Child Psychiatry Inpatient Service, Overland Park, Kansas.

The authors have reported no funding for this work.

Author Contributions Conceptualization: Moeller, Reynoldson Data curation: Meeks Formal analysis: Moeller Methodology: Moeller Writing – original draft: Moeller, Meeks, Reynoldson Writing – review and editing: Douglass

Disclosure: Drs. Moeller, Reynoldson, Douglass and Ms. Meeks have reported no biomedical financial interests or potential conflicts of interest.

Correspondence to Karen E. Moeller, PharmD, BCPP, The University of Kansas, School of Pharmacy, 2010 Becker Drive, Room 2001, Lawrence, KS 66047; e-mail: kmoeller@kumc.edu

0890-8567/\$36.00/@2021 American Academy of Child and Adolescent Psychiatry

https://doi.org/10.1016/j.jaac.2021.08.018

REFERENCES

- Centers for Disease Control and Prevention. Benefits of Getting a COVID-19 Vaccine. Accessed July 2, 2021; https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html.
- Centers for Disease Control and Prevention. COVID data tracker. Accessed August 9, 2021; https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends.
- Scherer AM, Gedlinske AM, Parker AM, et al. Acceptability of adolescent COVID-19 vaccination among adolescents and parents of adolescents—United States, April 15-23, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:997-1003. https://doi.org/10.15585/ mmwr.mm7028e1.
- Murphy J, Vallieres F, Bentall RP, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun. 2021;12:29. https://doi.org/10.1038/s41467-020-20226-9.
- Bickel S, Harris C, Huxol H, Morton R. COVID-19 vaccination outcomes at a pediatric long-term care facility. Pediatr Infect Dis J. 2021;40:e281-e283. https://doi.org/10.1097/ INF.000000000003185.
- Mazereel V, Van Assche K, Detraux J, De Hert M. COVID-19 vaccination for people with severe mental illness: Why, what, and how? Lancet Psychiatry. 2021;8:444-450. https://doi.org/10.1016/S2215-0366(20)30564-2.
- Miles LW, Williams N, Luthy KE, Eden L. Adult vaccination rates in the mentally ill population: An outpatient improvement project. J Am Psychiatr Nurses Assoc. 2020;26: 172-180. https://doi.org/10.1177/1078390319831763.

Virtual Arts and Movement Therapies for Youth in the Era of COVID-19

To the Editor:

he COVID-19 pandemic has had a significant impact on youth, including through increased isolation, the transition to online schooling, decreased access to arts and sports programming, exposure to illness, and anxiety. The pandemic has also affected the delivery of therapeutic services at a time when youth have needed more help building coping skills and reducing stress. Creative arts and movement therapies promote creativity and adaptability to better develop cognitive flexibility¹ while enhancing self-regulation and self-direction, adaptive skills that are protective in the face of stress.² Creative arts and movement-based group therapies delivered through community settings-such as resettlement agencies, schools, and community recreation centers-are feasible, costeffective, and increase accessibility, especially for populations often underrepresented in the therapeutic space.³ Offering such interventions at the group level benefits both those who are experiencing significant stress and anxiety^{4,5} and those who are not experiencing such symptoms, as they still reap the long-term benefits of building stress-relaxation and emotion regulation skills. Having previously demonstrated the efficacy of art therapy (AT) and dance/movement therapy (DMT) in improving posttraumatic stress and anxiety symptoms for youth,^{4,5} our laboratory-the Stress, Trauma, and Anxiety Research Clinic-shifted programming to virtual formats, in partnerships with local resettlement agencies and schools.

Throughout the pandemic, we have brought AT to youths resettled as refugees, as well as DMT to school children in high-risk, low-resource regions via online formats. Sessions are led by certified art therapists and dance/ movement therapists who also hold a joint master's degree in counseling; the team was supported by a psychiatrist specializing in trauma-informed care. Case managers from resettlement agencies and educators from schools shadow sessions and have the opportunity to learn and to adapt techniques from the therapeutic space for their clients and classrooms well beyond the end of programming. This integration also allows for transference of trusting rapport to facilitators, with whom participants may never have had the chance to meet in person. For youths resettled as refugees, AT is delivered weekly via Zoom, and case managers provide Zoom literacy trainings in advance of programming. For youth in high-risk, low-resource regions, DMT is delivered during their regular school day via students' online